NOISESaved copy
Coverage history

Assembled by NOISE.

Saved report copy

Recorded

Moderna and Merck mRNA vaccine cuts melanoma death and recurrence by 42%

Moderna and Merck announced their personalized mRNA cancer vaccine combined with Keytruda cut the risk of melanoma recurrence or death by 42% in a Phase 3 trial. Among 1,137 patients with surgically removed stage IIB-IV melanoma, 82% of those on the vaccine combination were alive without recurrence after two years, versus 70% receiving Keytruda alone. The results, scheduled for presentation at the European Society of Medical Oncology meeting in Madrid, are the first late-stage evidence of an mRNA vaccine improving outcomes over standard-of-care immunotherapy. The companies are discussing approval with regulators.